Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Connelly | $608,400 | $0 | $0 | $1,093,421 | $334,620 | $0 | $0 | $2,036,441 |
| President, Chief Executive Officer, and Director | ||||||||
| Christopher Haqq | 507,807 | 0 | 0 | 205,365 | 213,280 | 0 | 0 | 926,452 |
| Executive Vice President, Head of Research and Development and Chief Medical Officer | ||||||||
| Peter DeMuth | 460,000 | 0 | 0 | 218,071 | 188,600 | 0 | 0 | 866,671 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Robert Connelly | $2,036,441 | $678,300 | — | +1,358,141 |
| Christopher Haqq | 926,452 | 673,821 | — | +252,631 |
| Peter DeMuth | 866,671 | 502,636 | — | +364,035 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Preetam Shah | See Remarks | 2025-04-15 | A | 191,624 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Allen Nissenson | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julian Adams | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert R. Ruffolo | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen J. Wilson | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yekaterina (Katie) Chudnovsky | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jay Venkatesan | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol Ashe | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yekaterina (Katie) Chudnovsky | Director | 2025-06-03 | A | 103,225 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2025-12-09 | A | 362 | 4 | 1,596 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-09 | — | 362 | — | — | 1 insider, 1 accrual row | ||
| Preetam Shah | See Remarks | 2026-02-02 | A | 24,000 | 0 | 0 | Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-02-02 | A | 41,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-02-02 | A | 50,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-02-02 | A | 73,600 | 0 | 0 | Common | Form 4 ↗ |
| Preetam Shah | See Remarks | 2026-02-02 | A | 47,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-02-02 | A | 147,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-02-02 | A | 20,800 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-02-02 | A | 25,400 | 0 | 0 | Common | Form 4 ↗ |
| Preetam Shah | See Remarks | 2026-07-16 | A | 60,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-07-16 | A | 52,832 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-07-16 | A | 64,643 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-07-16 | A | 186,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Preetam Shah | See Remarks | 2025-04-15 | A | 191,624 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Allen Nissenson | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julian Adams | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert R. Ruffolo | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen J. Wilson | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yekaterina (Katie) Chudnovsky | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jay Venkatesan | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol Ashe | Director | 2025-05-19 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yekaterina (Katie) Chudnovsky | Director | 2025-06-03 | A | 103,225 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2025-12-09 | A | 362 | 4 | 1,596 | Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2025-12-09 | D | 362 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preetam Shah | See Remarks | 2026-02-02 | A | 24,000 | 0 | 0 | Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-02-02 | A | 41,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-02-02 | A | 50,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-02-02 | A | 73,600 | 0 | 0 | Common | Form 4 ↗ |
| Preetam Shah | See Remarks | 2026-02-02 | A | 47,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-02-02 | A | 147,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-02-02 | A | 20,800 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-02-02 | A | 25,400 | 0 | 0 | Common | Form 4 ↗ |
| Preetam Shah | See Remarks | 2026-07-16 | A | 60,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter DeMuth | Chief Scientific Officer | 2026-07-16 | A | 52,832 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Haqq | See Remarks | 2026-07-16 | A | 64,643 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Connelly | Director | 2026-07-16 | A | 186,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Robert Connelly | OPTION | 2024-09-01 | — | — | 91,600 | — | — |
| Robert Connelly | OPTION | 2024-02-01 | — | — | 225,137 | — | — |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Connelly | Option | 91,600 | 5.03 | — |
| Robert Connelly | Option | 36,975 | 3.86 | — |
| Christopher Haqq | Option | 2,826 | 13.81 | — |
| Peter DeMuth | Option | 29,800 | 4.5 | — |
| Christopher Haqq | Option | 28,200 | 4.5 | — |
| Peter DeMuth | Option | 29,800 | 5.03 | — |
| Robert Connelly | Option | 225,137 | 4.5 | — |
| Christopher Haqq | Option | 30,516 | 3.86 | — |
| Peter DeMuth | Option | 18,557 | 3.86 | — |
| Christopher Haqq | Option | 28,200 | 5.03 | — |
| Peter DeMuth | Option | 4,523 | 13.81 | — |
Elicio seeks to ensure total compensation paid to executive officers is reasonable and competitive, structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Julian Adams, Ph.DIndependent · Board Chair · Nominating/Governance (Chair) | $87,375 | $0 | $17,148 | — | $0 | $104,523 |
| Carol AsheIndependent · Audit · Compensation (Chair) · Nominating/Governance | 62,500 | 0 | 17,148 | — | 0 | 79,648 |
| Karen J. WilsonIndependent · Audit (Chair) · Nominating/Governance | 60,000 | 0 | 17,148 | — | 0 | 77,148 |
| Allen R. Nissenson, M.DIndependent · Audit · Compensation | 48,125 | 0 | 17,148 | — | 0 | 65,273 |
| Robert R. Ruffolo, Jr., Ph.D., FCPPIndependent · Compensation | 45,000 | 0 | 17,148 | 0 | 0 | 62,148 |
| Robert R. Ruffolo Jr., Ph.D., FCPPIndependent · Compensation | 45,000 | 0 | 17,148 | — | 0 | 62,148 |
| Yekaterina (Katie) ChudnovskyNot independent | 43,569 | 0 | 17,148 | — | 0 | 60,717 |
| Jay R. Venkatesan, M.DNot independent | 40,000 | 0 | 17,148 | — | 0 | 57,148 |
| Robert ConnellyEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $17,148 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $431,569 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $431,569 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Elicio Therapeutics, Inc. | 2024 | Robert Connelly | $608,400 | $0 | $1,093,421 | $334,620 | $2,036,441 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Connelly | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “2024 Summary Compensation Table” · page 24. As printed: 2,036,441. Filing ↗machine: t15 · r2 · c19 · span 308881–308890 |
| 2 | Section 01, Christopher Haqq | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “2024 Summary Compensation Table” · page 24. As printed: 926,452. Filing ↗machine: t15 · r5 · c19 · span 315665–315672 |
| 3 | Section 01, Peter DeMuth | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “2024 Summary Compensation Table” · page 24. As printed: 866,671. Filing ↗machine: t15 · r8 · c19 · span 321947–321954 |
| 4 | Section 03, Robert Connelly OPTION | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 333958–333964 |
| 5 | Section 03, Robert Connelly OPTION | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 333452–333459 |
| 6 | Section 08, Julian Adams, Ph.D | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 104,523. Filing ↗machine: t17 · r2 · c8 · span 439815–439822 |
| 7 | Section 08, Carol Ashe | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 79,648. Filing ↗machine: t17 · r3 · c8 · span 441530–441536 |
| 8 | Section 08, Karen J. Wilson | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 77,148. Filing ↗machine: r7 · c8 · span 448321–448327 |
| 9 | Section 08, Allen R. Nissenson, M.D | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 65,273. Filing ↗machine: r4 · c8 · span 443226–443232 |
| 10 | Section 08, Robert R. Ruffolo, Jr., Ph.D., FCPP | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 62,148. Filing ↗ |
| 11 | Section 08, Robert R. Ruffolo Jr., Ph.D., FCPP | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 62,148. Filing ↗ |
| 12 | Section 08, Yekaterina (Katie) Chudnovsky | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 60,717. Filing ↗machine: t17 · r5 · c8 · span 444930–444936 |
| 13 | Section 08, Jay R. Venkatesan, M.D | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 57,148. Filing ↗machine: r8 · c8 · span 450016–450022 |
| 14 | Section 08, Robert Connelly | DEF 14A | 2025-04-09 | 0001601485-25-000062 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Preetam Shah 2025-04-15 | Form 4 | 2025-04-16 | 0001601485-25-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Allen Nissenson 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Julian Adams 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Robert R. Ruffolo 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Karen J. Wilson 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Yekaterina (Katie) Chudnovsky 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Jay Venkatesan 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Carol Ashe 2025-05-19 | Form 4 | 2025-05-20 | 0001601485-25-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Yekaterina (Katie) Chudnovsky 2025-06-03 | Form 4 | 2025-06-04 | 0000950170-25-081741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Peter DeMuth 2025-12-09 | Form 4 | 2025-12-10 | 0001601485-25-000130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Peter DeMuth 2025-12-09 | Form 4 | 2025-12-10 | 0001601485-25-000130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Preetam Shah 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Peter DeMuth 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Christopher Haqq 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Robert Connelly 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Preetam Shah 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Robert Connelly 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Peter DeMuth 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Christopher Haqq 2026-02-02 | Form 4 | 2026-02-03 | 0001601485-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Preetam Shah 2026-07-16 | Form 4 | 2026-07-17 | 0001787403-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Peter DeMuth 2026-07-16 | Form 4 | 2026-07-17 | 0001979163-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Christopher Haqq 2026-07-16 | Form 4 | 2026-07-17 | 0001612095-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Robert Connelly 2026-07-16 | Form 4 | 2026-07-17 | 0001796436-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 39 | Section 09b board cost (computed) | Computed | — | computed | Cash 431,569 + equity 0 + all other 0 = 431,569, summed across the director compensation table rows.machine: formula: Σ = 431,569 |
| 40 | Elicio Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-04-09 | 0001601485-25-000062 | CEO total compensation as printed in Elicio Therapeutics, Inc.'s own proxy. As printed: 2,036,441. Filing ↗machine: t15 · r2 · c19 · span 308881–308890 |